{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:46:31Z","timestamp":1768646791805,"version":"3.49.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a serious pandemic. COVID-19 vaccination is urgent needed for limiting SARS-CoV-2 outbreaks by herd immunity. Simultaneously, post-marketing surveillance to assess vaccine safety is important, and collection of vaccine-related adverse events has been in progress. Vision-threatening ophthalmic adverse events of COVID-19 vaccines are rare but are a matter of concern. We report a 45-year-old Japanese male with positive for HLA-DR4\/HLA-DRB1*0405, who developed bilateral panuveitis resembling Vogt-Koyanagi-Harada (VKH) disease after the second dose of Pfizer-BioNTech COVID-19 mRNA (BNT162b2) vaccine. Glucocorticosteroid (GC) therapy combined with cyclosporine A (CsA) readily improved the panuveitis. The immune profile at the time of onset was analyzed using CyTOF technology, which revealed activations of innate immunity mainly consisting of natural killer cells, and acquired immunity predominantly composed of B cells and CD8<jats:sup>+<\/jats:sup> T cells. On the other hand, the immune profile in the remission phase was altered by GC therapy with CsA to a profile composed primarily of CD4<jats:sup>+<\/jats:sup> cells, which was considerably similar to that of the healthy control before the vaccination. Our results indicate that BNT162b2 vaccine may trigger an accidental immune cross-reactivity to melanocyte epitopes in the choroid, resulting in the onset of panuveitis resembling VKH disease.<\/jats:p>","DOI":"10.3389\/fimmu.2022.967972","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T07:50:02Z","timestamp":1664437802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine"],"prefix":"10.3389","volume":"13","author":[{"given":"Tomohito","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.762006","article-title":"Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after pfizer-BioNTech COVID-19 mRNA vaccination","volume":"12","author":"Hakroush","year":"2021","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019375","article-title":"An outbreak of covid-19 on an aircraft carrier","volume":"383","author":"Kasper","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050433","article-title":"An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times","volume":"9","author":"Garc\u00eda-Montero","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: Immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1976221","article-title":"Ocular adverse events after COVID-19 vaccination","volume":"29","author":"Ng","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40942-021-00319-3","article-title":"Vogt-Koyanagi-Harada syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine","volume":"7","author":"Saraceno","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1974492","article-title":"Vogt-Koyanagi-Harada disease associated with COVID-19 mRNA vaccine","volume":"29","author":"Koong","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Douglas","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(01)00925-4","article-title":"Revised diagnostic criteria for vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature","volume":"131","author":"Read","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1869-5760-3-43","article-title":"Drug-induced uveitis","volume":"3","author":"London","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659150","article-title":"Immune phenotyping of patients with acute vogt-Koyanagi-Harada syndrome before and after glucocorticoids therapy","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21858","article-title":"Multi-site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with maxpar pathsetter, an automated data analysis system","volume":"98","author":"Bagwell","year":"2020","journal-title":"Cytom B Clin Cytom"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1182\/blood.V130.Suppl_1.4818.4818","article-title":"Positive correlation between serum tryglycerides and pro-inflammatory cytokines in hemorrhagic fever with renal syndrome","volume":"130","author":"Kletenkov","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021","article-title":"Inflammatory factors of macular atrophy in eyes with neovascular age-related macular degeneration treated with aflibercept","volume":"12","author":"Sato","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000206","article-title":"Vogt\u2013Koyanagi\u2013Harada disease","volume":"26","author":"Burkholder","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1586\/eop.12.63","article-title":"Vogt\u2013Koyanagi\u2013Harada disease","volume":"7","author":"Attia","year":"2012","journal-title":"Expert Rev Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.10.4.263.15592","article-title":"Uveitis: A global perspective","volume":"10","author":"Chang","year":"2002","journal-title":"Ocul Immunol Inflammation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-1273","article-title":"T-Cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative vogt-Koyanagi-Harada uveitis","volume":"46","author":"Damico","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/srep06887","article-title":"Association of HLA-DR4\/HLA-DRB1*04 with vogt-Koyanagi-Harada disease: A systematic review and meta-analysis","volume":"4","author":"Shi","year":"2014","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000309240","article-title":"The role of cytotoxic T lymphocytes in the pathogenesis of vogt-Koyanagi-Harada disease","volume":"185","author":"Maezawa","year":"1982","journal-title":"Ophthalmologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2019.02.04","article-title":"Th Lymphocyte subsets in patients with vogt-Koyanagi-Harada disease","volume":"12","author":"Liang","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.01.010","article-title":"IL-23 promotes CD4+ T cells to produce IL-17 in vogt-Koyanagi-Harada disease","volume":"119","author":"Chi","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9863","article-title":"Decreased IL-27 expression in association with an increased Th17 response in vogt-Koyanagi-Harada disease","volume":"53","author":"Wang","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080090096030","article-title":"Class II major histocompatibility complex on melanocytes of vogt-Koyanagi-Harada disease","volume":"109","author":"Sakamoto","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00646.x","article-title":"B-lymphocyte contributions to human autoimmune disease","volume":"223","author":"Yanaba","year":"2008","journal-title":"Immunol Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/02713689008999417","article-title":"Immunohistochemical studies of vogt-Koyanagi-Harada disease with sunset sky fundus","volume":"9","author":"Inomata","year":"1990","journal-title":"Curr Eye Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000310145","article-title":"Studies on corticosteroid therapy in vogt-Koyanagi-Harada disease","volume":"201","author":"Sasamoto","year":"1990","journal-title":"Ophthalmologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1190oa","article-title":"The mechanism of action of methylprednisolone in the treatment of multiple sclerosis","volume":"11","author":"Sloka","year":"2005","journal-title":"Mult Scler"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.58472","article-title":"Low-dose cyclosporine treatment for sight-threatening uveitis: Efficacy, toxicity, and tolerance","volume":"58","author":"Mathews","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: Recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000776","article-title":"COVID-19 and autoimmune diseases","volume":"33","author":"Liu","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.265","article-title":"Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent vogt-Koyanagi-Harada disease","volume":"128","author":"Li","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10792-006-9020-y","article-title":"Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with vogt-Koyanagi-Harada disease","volume":"27","author":"Sugita","year":"2007","journal-title":"Int Ophthalmol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.967972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T07:50:10Z","timestamp":1664437810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.967972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2022.967972"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.967972","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"967972"}}